Fig. 2: Elevated levels of tumor scIgGs promoted tumor growth and tumor initiation.
From: Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions
a–c Detection of scIgGs in tumor tissues using immune florescence (IF) imaging method. A representative image is shown for each tumor group and scale bars are indicated on each images. Five tumor slides (n = 5) in each group were stained using IF imaging method and 4 images were collected per tumor slides. Images in (a) shows scIgG staining between BT474-IdeS and control BT474 tumors. Images in (b) shows scIgG staining between 4T1-IdeS and control 4T1 tumors. Images in (c) shows comparison of scIgG staining between PyMT+/scIgG+ tumors and PyMT+ control tumors. AHA monoclonal antibody (2095-2) was conjugated with DyLight (red color) using a commercial conjugation kit (Thermo Fisher) for detection of scIgGs in tumor tissues. d Tumor growth of BT474-IdeS cancer cells in vivo was significantly faster than the control (BT474) tumors, p < 0.05, n = 5. Both cancer cell lines were subcutaneously implanted into mammary fat pads (n = 5) with 5 × 106 cells/mouse, and tumor sizes were measured twice weekly. The tumor volume was calculated as described in the method. e BT474-IdeS tumors were larger than BT474 control and tumor images were taken after harvesting tumor at the end of in vivo study. 4T1-IdeS murine tumor cells showed faster tumor growth than the 4T1 control tumor cells (f) and larger tumor weights (g) than the counterpart 4T1 control tumors. Y-axis indicates mean ± standard deviation (SD), n = 5. Tumor cells (1 × 106 cells/mouse) were implanted at mouse mammary fat pads and mice were sacrificed when tumor burden in 4T1-IdeS group reached to a maximum (<10% of mouse body weight). Tumor volumes are calculated using the formula described in method and tumor weights were weighted using a balance, *p < 0.05, n = 5. h Tumor growth rate was significantly higher in scIgG containing (PyMT+/scIgG+) tumors than in that in control MMTV-PyMT (PyMT+) transgenic mice, n = 22 per group and *, for p < 0.05. Initiations of spontaneous mammary tumors were monitored every other day for palpable tumor formation and mouse age with detection of any palpable tumors was recorded. Tumor growth rate was calculated using the formula: {total tumor weight (ug)/days of tumor lasted from palpable tumor initiation}. i PyMT+/scIgG+ double transgenic mouse group had spontaneous mammary tumor initiation at younger age in comparison with PyMT+ the control mouse group, n = 22, * for p < 0.05.
